Pharma Business - September 15, 2021
Diamyd acquires property with manufacturing facility in Umeå
Diamyd Medical has announced the acquisition of the property in Umeå where production of the recombinant protein GAD65, the active component in the therapeutic diabetes vaccine Diamyd is being established. “The manufacturing facility is a crucial investment for the future and the acquisition gives us further opportunities to scale up and expand our manufacturing activities,” […]
Biotech Business - September 9, 2021
Diamyd Medical raises 150 million SEK
Diamyd Medical has successfully completed a directed share issue of 5 357 143 B-shares at a price of SEK 28 per share. Through the Directed Share Issue, the company will receive gross proceeds of SEK 150 million. The Directed Share Issue was subscribed by qualified investors, states the company. ”The company is developing strongly and […]
Intellectual Property - September 8, 2021
Diamyd Medical secures precision medicine patent
The European Patent Office has informed Diamyd Medical that the company’s patent application regarding prevention and treatment of autoimmune diabetes in individuals carrying the HLA DR3-DQ2 gene will be granted. The patent is valid until 2035 and provides central protection in Europe for the treatment or prevention of genetically defined autoimumune diabetes using GAD, which […]
Pharma Business - December 16, 2020
AI solutions to be tested at Diamyd’s vaccine facility
A new AI solution for sustainable production is to be tested at Diamyd Medical’s vaccine manufacturing facility in Umeå. It is hoped, once the solution has been refined, that it can be introduced in companies throughout Sweden. “This represents a unique opportunity that we do not see that often in Sweden. We are happy to […]
MedTech Business - August 6, 2016
Diamyd climbs after new announcements
Diamyd Medical has signed an agreement with Janssen Research & Development, the Juvenile Diabetes Research Foundation (JDRF) and the University of Alabama at Birmingham regarding the ongoing clinical trial “Effect of GABA or Combination GABA/GAD on the Progression of Type 1 Diabetes Mellitus in Children”. The agreement entails that Janssen Research & Development and JDRF […]
Acquisition - April 20, 2016
Diamyd increases investment in Cellaviva
Diamyd Medical has announced that the company has increased its investment in the associated company Cellaviva with an additional SEK 1.3 million. The investment is made within the framework of a convertible loan of SEK 2.7 million, mainly directed at existing shareholders. The convertible loan will, among others, be used to finance Cellaviva’s development of existing service […]
